Pages that link to "Q69968310"
Jump to navigation
Jump to search
The following pages link to Premarketing observational studies of population pharmacokinetics of new drugs (Q69968310):
Displaying 31 items.
- Increased oral ganciclovir bioavailability in HIV-infected patients with chronic diarrhoea and wasting syndrome--a population pharmacokinetic study (Q28367559) (← links)
- Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data (Q30661187) (← links)
- Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients (Q30827141) (← links)
- Estimation of pharmacokinetic parameters based on the patient-adjusted population data (Q31082856) (← links)
- A semiparametric method for describing noisy population pharmacokinetic data (Q32050016) (← links)
- Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis (Q33364323) (← links)
- Population pharmacokinetics. A regulatory perspective. (Q33714243) (← links)
- Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis (Q33937539) (← links)
- Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel (Q34273666) (← links)
- Population pharmacokinetics: theory and practice (Q34358724) (← links)
- How can we do pharmacokinetic studies in the tropics? (Q34387231) (← links)
- Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science (Q36311608) (← links)
- A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer (Q36695817) (← links)
- Pharmacokinetic and pharmacodynamic data and models in clinical trials (Q36765400) (← links)
- Sparse data analysis (Q36765409) (← links)
- Evolution of pharmacokinetics and pharmacokinetic/dynamic correlations during the 20th century (Q40749507) (← links)
- Identification of populations at risk in drug testing and therapy: application to elderly patients (Q40827219) (← links)
- Pharmacokinetics and pharmacodynamics of clozapine (Q40886861) (← links)
- Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective (Q40899599) (← links)
- Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies (Q43988070) (← links)
- Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. (Q44108202) (← links)
- A population pharmacokinetic model for docetaxel (Taxotere): model building and validation (Q46171352) (← links)
- Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy: a population pharmacokinetics analysis using nonlinear mixed-effects modelling (Q46332430) (← links)
- Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis (Q50920500) (← links)
- Detection of Carbamazepine-induced Changes in Valproic Acid Relative Clearance in Man by Simple Pharmacokinetic Screening (Q50922215) (← links)
- Evaluation of population (NONMEM) pharmacokinetic parameter estimates (Q51736552) (← links)
- Population pharmacokinetic analysis of bisoprolol (Q69371504) (← links)
- Relevance of genetic polymorphism in drug metabolism in the development of new drugs (Q69535480) (← links)
- The international conference on harmonisation (Q71814957) (← links)
- Predictive performance of population pharmacokinetic parameters of tianeptine as applied to plasma concentrations from a post-marketing study (Q72564508) (← links)
- Multiple-dose pharmacokinetics of a long half-life drug: contributions of mathematical modeling (Q73567824) (← links)